

Online supplementary material for

Title: Post-viral parenchymal lung disease of COVID-19 and viral pneumonitis: A systematic review and meta-analysis.

Table of Contents

Supplementary Table 1. Risk of bias assessment, observational studies	3
Supplementary Table 2. Risk of bias assessment, randomized control trial	5
Supplementary Table 3. GRADE approach to rate confidence in the estimates	6
Supplementary Figure 1. MEDLINE search strategy (OVID).....	7
Supplementary Figure 2. Risk of bias assessment, observational studies	9
Supplementary Figure 3. Radiological findings at baseline and follow-up in Influenza and SARS-CoV studies.....	10
Supplementary Figure 4. Subgroup analysis by study design - SARS-CoV- 2	11
Supplementary Figure 5. Subgroup analysis by ventilation - SARS-CoV- 2	12
Supplementary Figure 6. Subgroup analysis by mechanical ventilation- SARS-CoV- 2	13
Supplementary Figure 7. Subgroup analysis by age- SARS-CoV- 2.....	14
Supplementary Figure 8. Subgroup analysis by sex- SARS-CoV- 2.....	15
Supplementary Figure 9. Findings at follow-up, subgroup analysis by study design- all viruses	16
Supplementary Figure 10. Findings at follow-up, subgroup analysis by ARDS- all viruses.....	17
Supplementary Figure 11. Findings at follow-up, subgroup analysis by mechanical ventilation- all viruses	18

Supplementary Table 1. Risk of bias assessment, observational studies. Adapted from the CLARITY Group at McMaster University

Author(s)	Year	1. Can we be confident in the assessment of exposure?	2. Can we be confident that the outcome of interest was not present at start of study?	3. Did the study match the group(s) for all variables that are associated with the outcome of interest or did the statistical analysis adjust for these prognostic variables?	4. Can we be confident in the assessment of the presence or absence of prognostic factors?	5. Can we be confident in the assessment of outcome?	6. Was the follow up of cohorts adequate?	7. Were co-interventions similar between groups?
Winterbauer, R. H., et al	1977	V. Low	High	V. High	V. High	V. Low	Low	N/A
Antonio, G. E., et al.	2003	Low	V. Low	High	High	Low	High	Low
Jin, Z. Y., et al.	2003	V. Low	V. Low	N/A	Low	Low	Low	N/A
Liu, T., et al.	2003	V. Low	V. Low	High	Low	V. Low	High	N/A
Peng, M., et al.	2003	V. Low	V. Low	Low	Low	High	V. Low	N/A
Chiang, C. H., et al.	2004	V. Low	High	N/A	Low	Low	Low	N/A
Hsu, H. H., et al.	2004	V. Low	Low	High	High	V. Low	High	V. Low
Ng, C. K., et al.	2004	V. Low	High	Low	High	V. Low	Low	V. Low
Wong, K. T., et al.	2004	V. Low	High	V. Low	High	V. Low	V. Low	N/A
Beijing Respiratory Experts Pane	2005	V. Low	V. Low	N/A	V. Low	V. Low	Low	N/A
Chang, Y. C., et al	2005	V. Low	Low	High	Low	Low	High	V. Low
Hui D. S. et al.	2005	V. Low	Low	Low	Low	Low	High	Low
Ong, K. C., et al.	2005	Low	Low	V. Low	V. Low	V. Low	High	N/A
Xie, L., et al.	2005	V. Low	Low	Low	High	Low	Low	Low
Zheng, Z. G., et al.	2005	V. Low	V. Low	N/A	Low	Low	V. High	N/A
Li, T. S., et al.	2006	V. Low	High	Low	High	Low	Low	N/A
Tansey, C. M., et al.	2007	V. Low	V. Low	High	Low	V. Low	High	N/A
Lu PX, et al.	2010	V. Low	High	N/A	High	V. Low	V. Low	N/A
Bai, L., et al.	2011	Low	High	Low	Low	Low	V. High	High
Toufen, C., Jr., et al.	2011	V. Low	Low	N/A	V. High	Low	V. Low	N/A
Zarogoulidis, P., et al.	2011	V. Low	Low	N/A	Low	Low	V. Low	N/A
Luyt, C. E. et al.	2012	V. Low	V. Low	High	High	Low	V. Low	V. Low
Mineo, G., et al.	2012	V. Low	High	V. High	Low	V. Low	Low	N/A
Quispe-Laime, A. M., et al.	2012	V. Low	Low	N/A	V. High	Low	V. Low	N/A
Singh, V., et al.	2012	V. Low	High	N/A	V. High	Low	N/A	N/A
Edgeworth, D., et al.	2013	Low	High	N/A	V. High	V. Low	N/A	N/A
Dai, J., et al.	2014	Low	V. Low	N/A	V. High	V. Low	High	N/A
Liu, W., et al.	2015	High	Low	N/A	V. High	High	High	N/A
Wu X., et al.	2016	Low	High	N/A	High	V. Low	V. Low	N/A
Chen, J., et al.	2017	High	High	Low	High	Low	Low	Low
Hsieh, M. J., et al.	2018	V. Low	Low	V. High	V. High	V. Low	V. Low	N/A
Li, H., et al.	2018	V. Low	V. Low	Low	High	V. Low	V. Low	Low
Park, W. B., et al.	2018	V. Low	Low	N/A	High	V. Low	High	High
Saha, A., et al.	2018	V. Low	High	N/A	V. High	Low	V. Low	Low
Arnold, D. T., et al.	2020	V. Low	High	High	High	V. Low	Low	High
Daher, A., et al.	2020	V. Low	Low	V. High	Low	V. Low	V. Low	N/A
Huang, Y., et al.	2020	V. Low	Low	High	Low	V. Low	V. Low	Low

Li, R., et al.	2020	V. Low	High	V. High	V. High	V. Low	High	High
Liang, L., et al.	2020	V. Low	High	Low	Low	V. Low	High	N/A
Liu C., et al.	2020	V. Low	V. High	V. High	High	V. Low	V. Low	N/A
Liu D., et al.	2020	V. Low	High	V. High	Low	V. Low	V. Low	N/A
Liu X., et al.	2020	V. Low	High	High	High	V. Low	High	High
Lv, D., et al.	2020	V. Low	V. High	N/A	V. High	V. Low	V. Low	N/A
Shah, A. S., et al.	2020	V. Low	V. High	High	High	V. Low	High	N/A
Tabatabaei, S. M. H., et al.	2020	Low	High	Low	Low	V. Low	V. Low	Low
Wei J., et al.	2020	Low	V. High	High	High	V. Low	High	High
Yu M., et al.	2020	V. Low	V. High	High	High	High	V. Low	High
Zhao, Y. M., et al.	2020	V. Low	Low	Low	Low	V. Low	V. Low	Low
Zhong L., et al.	2020	Low	High	V. High	High	V. Low	V. High	High
Bellan M., et al.	2021	V. Low	V. High	Low	High	V. Low	V. High	N/A
de Graaf M.A., et al.	2021	V. Low	High	High	High	V. Low	Low	High
Guler S.A., et al.	2021	V. High	Low	Low	Low	V. Low	High	High
Han X., et al.	2021	V. Low	High	Low	V. High	V. Low	High	Low
Huang C., et al.	2021	Low	High	Low	Low	V. Low	High	N/A
Myall, K. J., et al.	2021	Low	V. High	High	High	V. Low	V. High	N/A
Ramani C, et al.	2021	Low	V. High	V. High	High	Low	High	N/A
Smet J., et al.	2021	V. High	V. High	V. High	High	V. Low	High	Low
van der Sar - van der Brugge S., et al.	2021	V. Low	V. High	High	High	V. Low	Low	High
van Gassel, R. J. J.	2021	V. Low	V. High	N/A	V. High	V. Low	High	N/A

Answer format:

Very high. Definitely High risk of bias: There is direct evidence of high risk of bias practices.

High. Probably High risk of bias: There is indirect evidence of high risk of bias practices OR there is insufficient information provided about relevant risk of bias practices.

Low. Probably Low risk of bias: There is indirect evidence of low risk of bias practices OR it is deemed by the risk of bias evaluator that deviations from low risk of bias practices for these criteria during the study would not appreciably bias results, including consideration of direction and magnitude of bias

Very low. Definitely Low risk of bias: There is direct evidence of low risk of bias practices

Supplementary Table 2. Risk of bias assessment, randomized control trial. From the CLARITY Group at McMaster University

Author(s)	Year	1. Was the allocation sequence adequately generated?	2. Was the allocation adequately concealed?	3. Blinding: Was knowledge of the allocated interventions adequately prevented?	4. Was loss to follow-up (missing outcome data) infrequent?	5. Are reports of the study free of selective outcome reporting?	6. Was the study apparently free of other problems that could put it at a risk of bias?
Chen, J., et al.	2006	V. Low	High	High	V. Low	V. Low	Low

Answer format:

Very high. Definitely High risk of bias: There is direct evidence of high risk of bias practices.

High. Probably High risk of bias: There is indirect evidence of high risk of bias practices OR there is insufficient information provided about relevant risk of bias practices.

Low. Probably Low risk of bias: There is indirect evidence of low risk of bias practices OR it is deemed by the risk of bias evaluator that deviations from low risk of bias practices for these criteria during the study would not appreciably bias results, including consideration of direction and magnitude of bias

Very low. Definitely Low risk of bias: There is direct evidence of low risk of bias practices

Supplementary Table 3. GRADE approach to rate confidence in the estimates

No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Certainty (overall score) ¹
a Outcome: Radiological sequelae - Fibrotic							
26	Observational studies	Moderate	High inconsistency	No serious indirectness	Moderate imprecision	Moderate	⊕○○○ Very low
b Outcome: Radiological sequelae - Inflammatory							
26	Observational studies	Moderate	High inconsistency	No serious indirectness	Moderate imprecision	Moderate	⊕○○○ Very low
c Outcome: Functional sequelae – Restrictive impairment							
21	Observational studies	Moderate	High inconsistency	No serious indirectness	Moderate imprecision	Moderate	⊕○○○ Very low
d Outcome: Functional sequelae – DLCO reduction							
23	Observational studies	Moderate	High inconsistency	No serious indirectness	Moderate imprecision	Moderate	⊕○○○ Very low

Grading of Recommendations, Assessment, Development and Evaluations

Risk of bias: All included studies with moderate risk of bias. The presence of the outcomes of interest at the beginning of the studies and possible confounding factors were not extensively assessed.

Inconsistency: High inconsistency with significant heterogeneity (I2 > 80%).

Indirectness: No serious indirectness. All study subjects had confirmed viral pneumonia, although severity and eligibility criteria were inconsistent.

Imprecision: Possible effect of sample size and selection.

Publication bias: Moderate: 28 papers published within 12 months from the outbreak (22 referring to SARS-CoV-2; 6 to SARS-CoV), 13 after 12 months (7 referring to SARS-CoV; 5 to Influenza; 1 to MERS-CoV)


¹ 4 ⊕⊕⊕⊕ **High** = This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different** is low.
 3 ⊕⊕⊕○ **Moderate** = This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different** is moderate.
 2 ⊕⊕○○ **Low** = This research provides some indication of the likely effect. However, the likelihood that it will be substantially different** is high.
 1 ⊕○○○ **Very low** = This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different** is very high.
 ** Substantially different = a large enough difference that it might affect a decision

Supplementary Figure 1. MEDLINE search strategy (OVID). Last carried out on 1st March 2021

1. viral pneumonia.mp. or Pneumonia, Viral/
2. Coronaviridae Infections/ or Coronavirus Infections/ or Infectious bronchitis virus/ or Coronaviridae/ or coronav*.mp. or Middle East Respiratory Syndrome Coronavirus/ or Coronavirus/
3. Betacoronavirus/ or Betacoronavirus 1/ or betacoronav*.mp.
4. severe acute respiratory syndrome.mp. or Severe Acute Respiratory Syndrome/
5. SARS Virus/ or sars.mp.
6. sars-cov-2.mp.
7. covid19.mp.
8. covid*.mp.
9. mers.mp. or Middle East Respiratory Syndrome Coronavirus/
10. Influenza A Virus, H7N9 Subtype/ or h7n9.mp. or Influenza A Virus, H5N1 Subtype/ or Influenza A virus/ or Influenza A Virus, H3N2 Subtype/ or Influenza A Virus, H1N2 Subtype/ or influenza*.mp. or Influenza A Virus, H1N1 Subtype/ or Influenza, Human/
11. Hospitalization/ or hospital*.mp.
12. Hypoxia/ or Oxygen Inhalation Therapy/ or oxygen therapy.mp.
13. Respiration, Artificial/ or invasive mechanical ventilation.mp. or Positive-Pressure Respiration/ or Respiratory Insufficiency/
14. Ventilation/ or Intermittent Positive-Pressure Ventilation/ or Noninvasive Ventilation/ or ventilation.mp. or Pulmonary Ventilation/
15. Noninvasive Ventilation/ or niv.mp.
16. Continuous Positive Airway Pressure/ or cpap.mp. or Positive-Pressure Respiration/
17. steroid*.mp.
18. Steroids/ or steroids*.mp.
19. Glucocorticoids/ or glucorticoids.mp.
20. antiviral.mp. or Antiviral Agents/
21. spirometry.mp. or Spirometry/
22. forced vital capacity.mp. or Vital Capacity/
23. fvc.mp.
24. forced expiratory volume.mp. or Forced Expiratory Volume/
25. fev1.mp.
26. total lung capacity.mp. or Total Lung Capacity/
27. tlc.mp.
28. dlco.mp. or Pulmonary Diffusing Capacity/
29. tlco.mp.
30. pulmonary function test.mp. or Respiratory Function Tests/

31. lung function*.mp.
32. Tomography, X-Ray Computed/ or ct.mp.
33. computed tomography.mp.
34. computer assisted tomography.mp.
35. fibrosis.mp. or Fibrosis/ or Pulmonary Fibrosis/
36. Bronchiolitis Obliterans/ or lung fibro*.mp.
37. hrct.mp.
38. high resolution computer tomography.mp. or Lung Diseases, Interstitial/
39. reticulation.mp.
40. fibrosing alveolitis.mp. or Pulmonary Fibrosis/
41. traction bronchiectasis.mp.
42. ground glass*.mp.
43. ggo.mp.
44. honeycombing.mp.
45. septal thickening.mp.
46. lung distortion.mp.
47. fibrotic disease.mp.
48. restrictive impairment.mp.
49. restrictive test.mp.
50. Cryptogenic Organizing Pneumonia/ or cryptogenic organising pneumonia.mp.
51. bronchiolitis obliterans organizing pneumonia.mp. or Cryptogenic Organizing Pneumonia/
52. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
53. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
54. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51
55. 52 and 53 and 54
56. limit 55 to (humans and "all adult (19 plus years)")


Supplementary Figure 2. Risk of bias assessment, observational studies



Supplementary Figure 3. Radiological findings at baseline and follow-up in Influenza and SARS-CoV studies

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow-up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months.



Supplementary Figure 4. Subgroup analysis by study design - SARS-CoV- 2

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months.



Supplementary Figure 5. Subgroup analysis by ventilation - SARS-CoV- 2

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months



Supplementary Figure 6. Subgroup analysis by mechanical ventilation- SARS-CoV- 2

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months



Supplementary Figure 7. Subgroup analysis by age- SARS-CoV- 2

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months. Studies reporting median or mean age ≥ 50 were classified as 1.



Supplementary Figure 8. Subgroup analysis by sex- SARS-CoV- 2

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months. Studies reporting $\geq 50\%$ of cohort as male were classified as 1.



Supplementary Figure 9. Findings at follow-up, subgroup analysis by study design- all viruses

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.


Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months



Supplementary Figure 10. Findings at follow-up, subgroup analysis by ARDS- all viruses

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.

Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months



Supplementary Figure 11. Findings at follow-up, subgroup analysis by mechanical ventilation- all viruses

Estimates are reported as proportion of number of CT scans showing the outcome of interest (n) on the total number of exams performed (N) and 95% confidence interval.

Follow up visits performed within the first four weeks after discharge were categorised as 1 month, subsequent timepoints within three months were categorised as 3 month, similarly for 6 and 12 months

